Latest Hotspot

FDA approves XTANDI® for advanced prostate cancer treatment

24 November 2023
3 min read

Astellas Pharma Inc. along with Pfizer Inc. have declared that they have secured an endorsement from the FDA for a supplementary New Drug Application regarding XTANDI® (enzalutamide). This follows several sped-up development and scrutiny initiatives by the FDA including Priority Review designation, Fast Track designation, and Real-time Oncology Review, all of which were based on findings from the Phase 3 EMBARK study.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The endorsement of XTANDI, the exclusive androgen receptor signaling inhibitor licensed by the FDA, marks a landmark development in treatement of patients with nonmetastatic castration-sensitive prostate cancer that shows biochemical recurrence presenting increased risk for metastasis. Patients with nmCSPC who have high-risk BCR can receive XTANDI independently or together with a gonadotropin-releasing hormone analog therapy.

Rough estimates indicate that between 20-40% of men who have received definite treatments for prostate cancer, including radical prostatectomy, radiotherapy, or a combination, will exhibit biochemical recurrence within a decade. Nearly 90% of men suffering from high-risk BCR progress to metastatic disease, with nearly a third ending up in fatality due to their metastatic prostate cancer.

Courtney Bugler, the CEO of ZERO Prostate Cancer, reflected on the plight of these men who had prostate cancer, went into remission, but later was informed of a disease recurrence with potential for metastasis. The emotional burden is considerable. Courtney was positive about the approval of XTANDI, viewing it as an encouraging treatment choice that offers hope to patients and caregivers in these difficult times.

Chief Medical Officer of Strategic Innovation and Pharmacy, Dr. Neal Shore, MD, FACS, who has nearly four decades' worth of experience in treating prostate cancer patients, expressed the significance of this development. He stated, “The licensing of XTANDI for patients with nmCSPC with BCR exhibiting a high probability of metastasis is an important step forward. With enzalutamide, an androgen deprivation signaling inhibitor, now being part of the standard discussion for patient-physician decision-making."

XTANDI is presently being reviewed for approval by a number of other global health regulatory bodies, including the European Medicines Agency. The drug is being evaluated for a broader indication in nmHSPC with high-risk BCR based on outcomes from the EMBARK trial.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 23, 2023, there are 250 investigational drugs for the AR target, including 181 indications, 284 R&D institutions involved, with related clinical trials reaching 2132, and as many as 182253 patents.

XTANDI® (enzalutamide) is an androgen receptor signaling inhibitor. XTANDI is currently approved for one or more of these indications in more than 90 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.

图形用户界面, 文本, 应用程序

描述已自动生成

Decoding Axatilimab: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
Decoding Axatilimab: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
24 November 2023
On 11 Dec 2023, the updated clinical results of Axatilimab at 3 different doses in patients with Chronic Graft-Versus-Host Disease (AGAVE-201) will be reported in 2023 ASH.
Read →
Q32 Bio retrieves global rights for Bempikibart (ADX-914) back from Amgen
Latest Hotspot
3 min read
Q32 Bio retrieves global rights for Bempikibart (ADX-914) back from Amgen
24 November 2023
Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.
Read →
What are DPP-4 inhibitors and how do you quickly get the latest development progress?
What are DPP-4 inhibitors and how do you quickly get the latest development progress?
24 November 2023
The application of DPP-4 inhibitors brings new hope to the treatment of Type 2 Diabetes.
Read →
Argenx announces EU approval for subcutaneous VYVGART® to treat Generalized Myasthenia Gravis
Latest Hotspot
3 min read
Argenx announces EU approval for subcutaneous VYVGART® to treat Generalized Myasthenia Gravis
24 November 2023
argenx reveals green light from European Commission for the subcutaneous usage of VYVGART® (efgartigimod alfa) in treating Generalized Myasthenia Gravis.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.